Skip to content
OpenCapital
Get started

Recursion Pharmaceuticals, Inc. RXRX Current Portion of Long-Term Debt and Finance Lease Obligations

Current Portion of Long-Term Debt and Finance Lease Obligations at other companies

Lantheus Holdings logo
Lantheus HoldingsLNTH
——

Other financials

Income statement

See full
Revenue$6.5M-56.1%
Gross profit-$6.0M+15.0%
Operating income-$128.5M+32.8%
Net income-$117.5M+42.0%
EPS (diluted)-$0.22+56.0%

Balance sheet

See full
Cash & equivalents$665.2M+30.6%
Total debt$88.6M-24.6%
Total equity$1.0B+9.7%
Total assets$1.3B+2.6%

Cash flow

See full
Operating cash flow-$81.1M+38.5%
CapEx$258.0K-85.9%
Free cash flow-$81.4M+39.2%

Valuation

See full
Market cap$1.71B-23.7%
Enterprise value$1.14B-39.8%
P/S25.8×-11.8×

Profitability

See full
Gross margin7.2%—
Operating margin-881.3%-66.8pp
Net margin-842.9%-92.4pp
FCF margin-490.7%-102pp

Returns & leverage

See full
Return on equity-57.2%-14.4pp
Debt / equity0.1×0.0×
Current ratio5.5×+1.4×

Where this comes from

Reported directly by Recursion Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent.

The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Recursion Pharmaceuticals, Inc.'s current portion of long-term debt and finance lease obligations.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Recursion Pharmaceuticals, Inc.'s current portion of long-term debt and finance lease obligations?
Recursion Pharmaceuticals, Inc. (RXRX) reported current portion of long-term debt and finance lease obligations of $9.27M in Q1 2026.
How has Recursion Pharmaceuticals, Inc.'s current portion of long-term debt and finance lease obligations changed year-over-year?
Recursion Pharmaceuticals, Inc.'s current portion of long-term debt and finance lease obligations increased by 7.9% year-over-year, from $8.59M to $9.27M.
What is the long-term trend for Recursion Pharmaceuticals, Inc.'s current portion of long-term debt and finance lease obligations?
Over 2 years (2023 to 2025), Recursion Pharmaceuticals, Inc.'s current portion of long-term debt and finance lease obligations has grown at a 1389.1% compound annual growth rate (CAGR), from $41K to $9.09M.